Zacks: Analysts Expect Xeris Pharmaceuticals Inc (NASDAQ:XERS) Will Announce Quarterly Sales of $2.17 Million

Wall Street brokerages expect that Xeris Pharmaceuticals Inc (NASDAQ:XERS) will report sales of $2.17 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Xeris Pharmaceuticals’ earnings. The highest sales estimate is $2.70 million and the lowest is $1.80 million. Xeris Pharmaceuticals reported sales of $310,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 600%. The firm is expected to report its next earnings report on Tuesday, August 4th.

According to Zacks, analysts expect that Xeris Pharmaceuticals will report full-year sales of $15.01 million for the current year, with estimates ranging from $12.30 million to $18.10 million. For the next fiscal year, analysts anticipate that the company will post sales of $59.43 million, with estimates ranging from $54.10 million to $64.40 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Xeris Pharmaceuticals.

Xeris Pharmaceuticals (NASDAQ:XERS) last posted its earnings results on Thursday, May 7th. The company reported ($0.89) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.92) by $0.03. Xeris Pharmaceuticals had a negative net margin of 3,100.00% and a negative return on equity of 323.82%. The business had revenue of $1.68 million for the quarter, compared to analysts’ expectations of $1.82 million.

Several analysts have issued reports on XERS shares. Mizuho reiterated a “buy” rating and issued a $14.00 target price on shares of Xeris Pharmaceuticals in a research note on Tuesday, May 26th. Zacks Investment Research upgraded shares of Xeris Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a research report on Saturday. Finally, ValuEngine upgraded shares of Xeris Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 30th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Xeris Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $12.50.

NASDAQ XERS traded up $0.17 on Monday, hitting $2.68. The stock had a trading volume of 3,332,848 shares, compared to its average volume of 787,454. Xeris Pharmaceuticals has a 52-week low of $1.42 and a 52-week high of $12.94. The company has a debt-to-equity ratio of 2.16, a quick ratio of 4.72 and a current ratio of 4.82. The company has a market capitalization of $94.35 million, a price-to-earnings ratio of -0.56 and a beta of 2.10. The firm has a 50-day moving average of $4.64 and a 200-day moving average of $4.49.

In other news, insider John Patrick Shannon, Jr. purchased 22,000 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were acquired at an average price of $3.55 per share, with a total value of $78,100.00. Following the acquisition, the insider now directly owns 117,493 shares in the company, valued at $417,100.15. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Paul R. Edick purchased 33,000 shares of the business’s stock in a transaction on Friday, May 8th. The stock was purchased at an average cost of $3.54 per share, for a total transaction of $116,820.00. Following the acquisition, the insider now owns 95,493 shares in the company, valued at $338,045.22. The disclosure for this purchase can be found here. 5.95% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC bought a new stake in Xeris Pharmaceuticals in the 1st quarter worth $26,000. Deutsche Bank AG grew its holdings in Xeris Pharmaceuticals by 40.7% in the 1st quarter. Deutsche Bank AG now owns 13,617 shares of the company’s stock worth $27,000 after acquiring an additional 3,942 shares during the last quarter. Squarepoint Ops LLC bought a new stake in Xeris Pharmaceuticals in the 1st quarter worth $33,000. American International Group Inc. grew its holdings in Xeris Pharmaceuticals by 26.3% in the 1st quarter. American International Group Inc. now owns 21,090 shares of the company’s stock worth $41,000 after acquiring an additional 4,394 shares during the last quarter. Finally, M&T Bank Corp grew its holdings in Xeris Pharmaceuticals by 26.7% in the 1st quarter. M&T Bank Corp now owns 26,036 shares of the company’s stock worth $51,000 after acquiring an additional 5,493 shares during the last quarter. 62.48% of the stock is currently owned by institutional investors and hedge funds.

About Xeris Pharmaceuticals

Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.

Featured Story: What is the NASDAQ Stock Market?

Get a free copy of the Zacks research report on Xeris Pharmaceuticals (XERS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xeris Pharmaceuticals (NASDAQ:XERS)

Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.